TOLREMO therapeutics focuses on developing compounds to block mechanisms of non-genetic cancer drug resistance. They have developed lead candidate TT125-802, an orally available small molecule inhibitor targeting gene transcription involved in cancer cell resistance.

TOLREMO therapeutics

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 17, 2024 1:06 PM	7f9dbdf5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 17, 2024 10:09 PM	dc9bbf49
company summary	general
signals	general	Sep 17, 2024 1:06 PM	3c6ec44a
crunchbase trigger	general
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 17, 2024 1:06 PM	2c4f1ec3
news basic	general	Sep 17, 2024 1:06 PM	c05239fd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:TOLREMO

TOLREMO therapeutics